TheraPEAKTMX-VIVOTM 15, Serum-free hematopoietic cell medium, with L-Glutamine, without gentamicin and phenol red, xenofree, 1 L
TheraPEAK® T-VIVO® Cell Culture Medium, chemically defined, non-animal origin (NAO), serum-free, with recombinant proteins, 1 L bottle
Culture system containing S-ALITM Basal Media (CC-3281), S-ALITM Differentiation Media (CC-3282) and S-ALITM SingleQuotsTM supplements (CC-4538) required for air-liquid interface differentiation of small airway epithelial cells.
Insect-XPRESSTM Protein-free Insect Cell Medium with L-Glutamine, 1L
Culture system containing B-ALITM Basal Media (00193516), B-ALITM Differentiation Media (00193517) and B-ALITM SingleQuotsTM Supplements (00193515) required for air-liquid interface differentiation of bronchial epithelial cells.
ProCHO® 4 Protein-free CHO Medium with 0.1% Pluronic® F-68, without L-Glutamin, phenol red, hypoxanthine or thymidine, 1 L.
-
References - X-Vivo™Overview of relevant references
-
Primary Normal Human Cells and MediaIn Vivo Relevance. In Vitro Results. Updated and revised cell content.
-
TechSheet - X-VIVO™ Media SystemsInstructions for how to use the X-VIVO™ Media Series
-
TheraPEAK® T-VIVO® Cell Culture Medium – OverviewView or download this document for a comprehensive overview and learn how the chemically defined TheraPEAK® T-VIVO® Medium enhances T-cell culture and accelerates therapy development.
-
TheraPEAK® X-VIVO® Hematopoietic Cell Culture MediumSerum-free, GMP produced medium for cell therapy applications
-
Non-viral Gene Modification for Ex-vivo Cell TherapyIn this interview our Director Transfection R&D discusses the advantages of non-viral transfection technologies for CRISPR- or transposon-based genetic modification cell and gene therapy.
-
Terms and Conditions TheraPEAK T-VIVO Sample Request Program
-
4D-Nucleofector® LV Unit for Large-scale TransfectionEfficient, closed and scalable transfection for ex vivo cell and gene therapy applications
-
A Novel In Vitro Liver Cell Culture Flow System Allowing Long-Term Metabolism and Hepatotoxicity Studies]Manuscript published in Applied In Vitro Toxicology journal describes improvement of CYP450 phenotype of primary cryopreserved hepatocytes using Quasi Vivo® System
-
Clonetics™ and Poietics™ Disease CellsIn Vivo Relevance. In Vitro Results. Product listings on Poster Six disease cell lines are identified:Airway, Skeletal Muscle,Adipose, Cardiac, Renal and Dermal